Valemetostat + Darolutamide
Phase 1Recruiting 0 views this week 0 watching💤 Quiet
Interest: 36/100
36
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Metastatic Castration-resistant Prostate Cancer
Conditions
Metastatic Castration-resistant Prostate Cancer
Trial Timeline
Dec 3, 2025 → Nov 30, 2029
NCT ID
NCT07244341About Valemetostat + Darolutamide
Valemetostat + Darolutamide is a phase 1 stage product being developed by Daiichi Sankyo for Metastatic Castration-resistant Prostate Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07244341. Target conditions include Metastatic Castration-resistant Prostate Cancer.
What happened to similar drugs?
20 of 20 similar drugs in Metastatic Castration-resistant Prostate Cancer were approved
Approved (20) Terminated (8) Active (0)
Hype Score Breakdown
Clinical
6
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07244341 | Phase 1 | Recruiting |
Competing Products
20 competing products in Metastatic Castration-resistant Prostate Cancer